Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
نویسندگان
چکیده
منابع مشابه
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
BACKGROUND Dual delayed-release dexlansoprazole is approved for use in adults as a 30 mg orally disintegrating tablet (ODT) or as 30 mg and 60 mg capsules. The pharmacokinetics, pharmacodynamics, and safety profile of two dexlansoprazole 30 mg ODTs were compared with one dexlansoprazole 60 mg capsule in this randomized, phase I, open-label, single-center, multiple-dose, two-period crossover stu...
متن کاملNifedipineExtended-release Tablets, USP30 mg, 60 mg and 90 mg
Nifedipine Extended-release Tablet depends for its action on the existence of an osmotic gradient between the contents of the tablet core and fluid in the GI tract. Drug delivery is essentially constant as long as the osmotic gradient remains constant, and then gradually falls to zero. Upon swallowing, the biologically inert components of the tablet remain intact during GI transit and are elimi...
متن کاملBioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration
BACKGROUND Dexlansoprazole is a proton pump inhibitor (PPI) approved for use in dual delayed-release capsule and orally disintegrating tablet (ODT) formulations. AIM To assess effects of food, water, and route of administration on the bioavailability of dexlansoprazole 30-mg ODT. METHODS Two separate open-label, phase 1, single-dose crossover studies were conducted in healthy adults. In stu...
متن کاملComparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
BACKGROUND This paper describes a Phase 1, single-center, randomized, open-label, two-period crossover study which compared the pharmacodynamic effects of single doses of dexlansoprazole modified-release 60 mg and esomeprazole 40 mg on 24-hour intragastric pH in healthy adult subjects. METHODS Forty-four subjects aged 20-54 years were randomized in a 1:1 ratio to two sequence groups defining ...
متن کاملPREVACID (lansoprazole) Delayed-Release Capsules PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets For oral administration
-----------------------------DRUG INTERACTIONS-------------------------- • Atazanavir: Do not co-administer with atazanavir. (7.1) • Drugs with pH-Dependent Absorption: May interfere with the absorption of drugs where gastric pH is important for bioavailability. (7.1) • Warfarin: Concomitant warfarin use may require monitoring for increases in INR and prothrombin time. (7.2) • Tacrolimus: Conc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Gastroenterology
سال: 2016
ISSN: 1756-2848,1756-2848
DOI: 10.1177/1756283x16666800